MeiraGTx Holdings PLC (MGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MeiraGTx Holdings PLC (MGTX) has a cash flow conversion efficiency ratio of -8.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($46.63 Million) by net assets ($-5.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MeiraGTx Holdings PLC (MGTX) net asset quality to measure how much of total assets are equity-financed.
MeiraGTx Holdings PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MeiraGTx Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MeiraGTx Holdings PLC cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
MeiraGTx Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MeiraGTx Holdings PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GoGold Resources Inc.
TO:GGD
|
0.044x |
|
Yutong Optical
SHE:300790
|
0.026x |
|
CEVA Inc
NASDAQ:CEVA
|
0.026x |
|
SAF Holland SA
XETRA:SFQ
|
0.082x |
|
Oppenheimer Holdings Inc
NYSE:OPY
|
0.069x |
|
Kingenta Ecological Engineering Group Co Ltd
SHE:002470
|
-0.063x |
|
Xinlei Compressor Co. Ltd. A
SHE:301317
|
N/A |
|
Hangzhou Zhongtai Cryogenic Technology Corp
SHE:300435
|
0.067x |
Annual Cash Flow Conversion Efficiency for MeiraGTx Holdings PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of MeiraGTx Holdings PLC from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see MeiraGTx Holdings PLC (MGTX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.79 Million | $-46.36 Million | 8.003x | +619.44% |
| 2024-12-31 | $67.83 Million | $-104.50 Million | -1.541x | -102.04% |
| 2023-12-31 | $138.18 Million | $-105.36 Million | -0.763x | -22.82% |
| 2022-12-31 | $117.74 Million | $-73.10 Million | -0.621x | -993.13% |
| 2021-12-31 | $185.40 Million | $-10.53 Million | -0.057x | +78.82% |
| 2020-12-31 | $238.56 Million | $-63.97 Million | -0.268x | -355.23% |
| 2019-12-31 | $190.80 Million | $20.04 Million | 0.105x | +114.46% |
| 2018-12-31 | $81.06 Million | $-58.89 Million | -0.726x | -290.58% |
| 2017-12-31 | $-47.37 Million | $-18.06 Million | 0.381x | -54.53% |
| 2016-12-31 | $-17.14 Million | $-14.37 Million | 0.838x | -- |
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xe… Read more